The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1359
Alcaftadine (Lastacaft) for Allergic Conjunctivitis
The full article is available to subscribers Subscriber Login   

Alcaftadine (Lastacaft – Allergan), an ophthalmic H1-antihistamine, has been approved by the FDA for prevention of itching associated with allergic conjunctivitis in patients > 2 years old.

TREATMENT OF ALLERGIC CONJUNCTIVITIS — Allergic conjunctivitis is the most common form of ocular allergy. The main symptom, itching, can be relieved by an oral H1-antihistamine such as cetirizine (Zyrtec, and others; available over the counter) or fexofenadine (Allegra, and others; available over the counter). Ophthalmic antihistamines (Table 1) are also effective and have a more rapid onset of action (within a few minutes) than the oral drugs. Ophthalmic mast-cell stabilizers cromolyn (Crolom, and others), lodoxamide (Alomide), nedocromil (Alocril) and pemirolast (Alamast) have a slower onset ... more       Show References Hide References

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Immediate Online access to current issue and archives from 1988 to the present
  • Mobile access to our mobile site and free apps for iOS, Android and Kindle
  • FREE online per issue CME/CE
Free trial offer
3 Free Issues of The Medical Letter on Drugs and Therapeutics mailed to your home or office PLUS online access.
Try a Free Trial Subscription
Purchase this article:
Title: Alcaftadine (Lastacaft) for Allergic Conjunctivitis
Article code: 1359c
 Electronic, downloadable article - $25